Skip to content
HowShorted

Cidara Therapeutics, Inc. short interest in 2023

In 2023, Cidara Therapeutics, Inc.'s disclosed short interest ran from 1.01% of shares outstanding on 13 Jan 2023 to 1.12% on 29 Dec 2023, a change of +0.11 percentage points. The year's high was 4.33% on 28 Feb 2023 and its low 0.78% on 15 Dec 2023, averaging 2.04% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.85 days on 15 Nov 2023. Full history: Cidara Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Cidara Therapeutics, Inc. in 2023

2023 in figures

Start of year
1.01% (13 Jan 2023)
End of year
1.12% (29 Dec 2023)
Change
+0.11 pp
High
4.33% (28 Feb 2023)
Low
0.78% (15 Dec 2023)
Average
2.04%
Highest days to cover
5.85 (15 Nov 2023)
SEC filings marked
9

Every report in 2023

Cidara Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20231.01%1.01
31 Jan 20232.45%1.00
15 Feb 20232.77%1.07
28 Feb 20234.33%2.88
15 Mar 20233.03%1.00results (8-K)
31 Mar 20233.98%1.0010-K filed, results (8-K)
14 Apr 20233.46%1.88
28 Apr 20232.70%1.77
15 May 20232.49%1.4510-Q filed, results (8-K)
31 May 20232.15%1.69
15 Jun 20231.67%2.08
30 Jun 20231.96%2.46
14 Jul 20231.83%3.91
31 Jul 20231.72%2.32
15 Aug 20231.57%2.9110-Q filed, results (8-K)
31 Aug 20231.31%2.93
15 Sep 20231.73%1.34
29 Sep 20231.66%3.56
13 Oct 20231.46%4.66
31 Oct 20231.37%4.21
15 Nov 20231.36%5.8510-Q filed, results (8-K)
30 Nov 20231.02%2.79
15 Dec 20230.78%1.74
29 Dec 20231.12%1.00

See also: Cidara Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.